<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The aim of the present study was to investigate the effect of blood pressure lowering and intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control on the incidence and progression of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> in type 2 diabetic patients </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The Action in <z:mp ids='MP_0002055'>Diabetes</z:mp> and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">Vascular Disease</z:e>: Preterax and Diamicron <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> Controlled Evaluation (ADVANCE) <z:chebi fb="46" ids="15035">Retinal</z:chebi> Measurements study, a substudy of ADVANCE, is a randomised (using a central, computer-based procedure) controlled 2 x 2 factorial trial comprising a double-blind comparison of blood pressure lowering with <z:chebi fb="0" ids="8024">perindopril</z:chebi>-indapamide vs placebo, and an open comparison of standard vs intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control targeting a HbA(1c) of &lt; or = 6.5% in 1,602 diabetic patients from ADVANCE centres with access to <z:chebi fb="46" ids="15035">retinal</z:chebi> cameras conducted from 2001 to 2008 </plain></SENT>
<SENT sid="2" pm="."><plain>At baseline and the final visit, seven-field stereoscopic <z:chebi fb="46" ids="15035">retinal</z:chebi> photographs were taken and graded by blinded readers (gradeable baseline and final photographs from 1,241 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>Progression of &gt; or =2 steps in the Early Treatment of Diabetic <z:hpo ids='HP_0000488'>Retinopathy</z:hpo> Study classification (using the eye with worst grading) was the primary outcome </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0000488'>Retinopathy</z:hpo> progressed in 59 (4.8%) patients and developed in 128 (10.3%) patients over 4.1 years </plain></SENT>
<SENT sid="5" pm="."><plain>Fewer patients on blood pressure-lowering treatment (n = 623) experienced incidence or progression of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> compared with patients on placebo (n = 618), but the difference was not significant (OR 0.78; 95% CI 0.57-1.06; p = 0.12) </plain></SENT>
<SENT sid="6" pm="."><plain>Blood pressure-lowering treatment reduced the occurrence of macular <z:hpo ids='HP_0000969'>oedema</z:hpo> (OR 0.50; 95% CI 0.29-0.88; p = 0.016) and arteriovenous nicking compared with placebo (OR 0.60; 95% CI 0.38-0.94; p = 0.025) </plain></SENT>
<SENT sid="7" pm="."><plain>Compared with standard <z:chebi fb="105" ids="17234">glucose</z:chebi> control (n = 611), intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control (n = 630) did not reduce (p = 0.27) the incidence and progression of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> (OR 0.84; 95% CI 0.61-1.15) </plain></SENT>
<SENT sid="8" pm="."><plain>Lower, borderline significant risks of <z:e sem="disease" ids="C0333101" disease_type="Disease or Syndrome" abbrv="">microaneurysms</z:e>, hard exudates and macular <z:hpo ids='HP_0000969'>oedema</z:hpo> were observed with intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control, adjusted for baseline <z:chebi fb="46" ids="15035">retinal</z:chebi> haemorrhages </plain></SENT>
<SENT sid="9" pm="."><plain>These effects of the two treatments were independent and additive </plain></SENT>
<SENT sid="10" pm="."><plain>Adverse events in the ADVANCE study are reported elsewhere </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS/INTERPRETATION: Blood pressure lowering or intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control did not significantly reduce the incidence and progression of <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, although consistent trends towards a benefit were observed, with significant reductions in some lesions observed with both interventions </plain></SENT>
<SENT sid="12" pm="."><plain>TRIAL REGISTRATION: ClinicalTrials.gov ID no </plain></SENT>
<SENT sid="13" pm="."><plain>NCT00145925 </plain></SENT>
<SENT sid="14" pm="."><plain>FUNDING: Grants from Servier and the National Health and Medical Research Council of Australia </plain></SENT>
</text></document>